Last reviewed · How we verify

Erector Spinae Plane Block using 0.2% ropivacaine

Poznan University of Medical Sciences · FDA-approved active Small molecule Quality 5/100

Erector Spinae Plane Block using 0.2% ropivacaine is a Small molecule drug developed by Poznan University of Medical Sciences. It is currently FDA-approved.

The Erector Spinae Plane Block using 0.2% ropivacaine, developed by Poznan University of Medical Sciences, is a marketed local anesthetic technique. A key strength is the protection provided by a composition patent expiring in 2028. The primary risk is the lack of revenue data, which may affect investment and market confidence.

At a glance

Generic nameErector Spinae Plane Block using 0.2% ropivacaine
SponsorPoznan University of Medical Sciences
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Erector Spinae Plane Block using 0.2% ropivacaine

What is Erector Spinae Plane Block using 0.2% ropivacaine?

Erector Spinae Plane Block using 0.2% ropivacaine is a Small molecule drug developed by Poznan University of Medical Sciences.

Who makes Erector Spinae Plane Block using 0.2% ropivacaine?

Erector Spinae Plane Block using 0.2% ropivacaine is developed and marketed by Poznan University of Medical Sciences (see full Poznan University of Medical Sciences pipeline at /company/poznan-university-of-medical-sciences).

What development phase is Erector Spinae Plane Block using 0.2% ropivacaine in?

Erector Spinae Plane Block using 0.2% ropivacaine is FDA-approved (marketed).

Related